hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

SIMPLE SUMMARY: Recent clinical trials suggest that combination therapies that include either gemcitabine or 5-fluorouracil (5-FU) both give significant survival benefits for pancreatic cancer patients. The tumor level of the nucleoside transporter hENT1 is prognostic in patients treated with adjuva...

Descripción completa

Detalles Bibliográficos
Autores principales: Aughton, Karen, Elander, Nils O., Evans, Anthony, Jackson, Richard, Campbell, Fiona, Costello, Eithne, Halloran, Christopher M., Mackey, John R., Scarfe, Andrew G., Valle, Juan W., Carter, Ross, Cunningham, David, Tebbutt, Niall C., Goldstein, David, Shannon, Jennifer, Glimelius, Bengt, Hackert, Thilo, Charnley, Richard M., Anthoney, Alan, Lerch, Markus M., Mayerle, Julia, Palmer, Daniel H., Büchler, Markus W., Ghaneh, Paula, Neoptolemos, John P., Greenhalf, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616255/
https://www.ncbi.nlm.nih.gov/pubmed/34830914
http://dx.doi.org/10.3390/cancers13225758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616255/
https://www.ncbi.nlm.nih.gov/pubmed/34830914
http://dx.doi.org/10.3390/cancers13225758

Ejemplares similares